RXRX Company Profile and Key Details

Q: Who are the executives of RXRX?

Mr. Ryan KellyManaging DirectorDr. Michael Secora Ph.D.Chief Financial OfficerMs. Tina Marriott LarsonChief Operating Officer & PresMs. Louisa Daniels J.D., M.B.A.Chief Legal Officer & Gen. CounselKevin LeggatVice President of Fin. & AccountingDr. Blake C. Borgeson Ph.D.Co-Founder & DirectorDr. Christopher C. Gibson Ph.D.Co-Founder, Chief Executive Officer & DirectorMr. Benjamin Mabey M.S.Chief Technology OfficerDr. Shafique Virani M.D.Chief Corporation Devel. OfficerMr. Jared AllenbachSenior Director of Investor RelationsMs. Heather Kirkby M.B.A.Chief People Officer

NASDAQ : RXRX

Recursion Pharmaceuticals

$3.56

-0.34-8.72%

At Close 4:00 PM

73.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Recursion Pharmaceuticals, Inc. (RXRX) stock declined over -8.72%, trading at $3.56 on NASDAQ, down from the previous close of $3.90. The stock opened at $3.79, fluctuating between $3.54 and $3.88 in the recent session.

Stock Snapshot

3.9

Prev. Close

1.43B

Market Cap

3.54

Day Low

-1.93

P/E Ratio

-1.84

EPS (TTM)

-1.29

Cash Flow per Share

3.79

Open

400.82M

Number of Shares

3.875

Day High

77.49%

Free Float in %

1.99

Book Value

39.62M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	3.79	3.88	3.54	3.56	39.8M
Feb 04, 2026	4.12	4.13	3.71	3.90	36.56M
Feb 03, 2026	4.22	4.29	3.96	4.10	23.25M
Feb 02, 2026	4.12	4.26	4.08	4.18	17.33M
Jan 30, 2026	4.26	4.35	4.16	4.19	19.38M
Jan 29, 2026	4.44	4.48	4.30	4.32	17.23M
Jan 28, 2026	4.64	4.64	4.42	4.47	16.01M
Jan 27, 2026	4.64	4.74	4.49	4.60	15.58M
Jan 26, 2026	4.71	4.72	4.55	4.59	15.32M
Jan 23, 2026	4.90	4.96	4.70	4.73	18.16M
Jan 22, 2026	4.65	5.24	4.62	4.96	36.2M
Jan 21, 2026	4.42	4.68	4.35	4.61	26.82M
Jan 20, 2026	4.46	4.55	4.39	4.40	22M
Jan 16, 2026	4.65	4.88	4.55	4.67	21.19M
Jan 15, 2026	4.85	4.87	4.63	4.64	19.03M
Jan 14, 2026	4.62	4.87	4.61	4.85	16.7M
Jan 13, 2026	4.88	4.96	4.63	4.69	18.64M
Jan 12, 2026	4.76	4.98	4.72	4.81	24.44M
Jan 09, 2026	4.78	4.82	4.62	4.66	15.23M
Jan 08, 2026	4.80	4.80	4.65	4.70	17.03M

Contact Details

Salt Lake City, UT 84101

United States

https://www.recursion.com 385 269 0203

About Company

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.43-1.09%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $3.56 in the last trading session. During the trading session, RXRX stock reached the peak price of $3.88 while $3.54 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was -8.72% while the dollar amount for the price change in RXRX stock was - $0.34.

RXRX's industry and sector of operation?

The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RXRX?

Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer

How RXRX did perform over past 52-week?

RXRX's closing price is 0.56% higher than its 52-week low of $3.54 where as its distance from 52-week high of $12.36 is -71.2%.

How many employees does RXRX have?

Number of RXRX employees currently stands at 800.

Link for RXRX official website?

Official Website of RXRX is: https://www.recursion.com

How do I contact RXRX?

RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.

How many shares of RXRX are traded daily?

RXRX stock volume for the day was 39.62M shares. The average number of RXRX shares traded daily for last 3 months was 23.61M.

What is the market cap of RXRX currently?

The market value of RXRX currently stands at $1.43B with its latest stock price at $3.56 and 400.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	800
Beta	0.95
Sales or Revenue	$44.58M
5Y Sales Change%	19.78%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	800
Beta	0.95
Sales or Revenue	$44.58M
5Y Sales Change%	19.78%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RXRX Company Profile and Key Details

Recursion Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook